Debra Patt, MD, MPH, MBA, is a practicing oncologist and breast cancer specialist in Austin, Texas, and an executive vice president of Texas Oncology with responsibilities in healthcare policy and strategic initiatives. She is an active leader in breast cancer research, serves on the US Oncology Research Breast Cancer Committee, and chairs the breast cancer subsection of the pathways task force for The US Oncology Network. Dr. Patt has expertise in healthcare policy and has testified before Congress to protect access to care for Medicare beneficiaries. She is a leader in clinical cancer informatics, and is involved in system innovations to enhance care delivery across a national network of oncology practices.
Dr. Patt serves on the national board for the Community Oncology Alliance and local board of the Shivers Cancer Foundation. She is a nationally recognized leader in cancer research, has published many articles, and leads the service line for breast health services for the Dell Medical School.
Ray D. Page, DO, PhD, FACOI, FASCO, has practiced medical oncology for 23 years. He is President of The Center for Cancer and Blood Disorders, and has been at the forefront of community oncology practice transformation participating in a variety of payment reform models and development of pathway systems. As Director of Research for The Center for Cancer and Blood Disorders, Dr. Page has been the Principal Investigator of over 200 clinical trials and is well published on a variety of cancer-related topics. He has a particular interest in healthcare policy and was recently acknowledged as the American Society of Clinical Oncology (ASCO) Advocate of the Year.
Dr. Page actively serves ASCO, including as the current Chair of the Clinical Practice Committee, Nominating Committee, Government Relations Committee, ASCO Delegate to the AMA House of Delegates, and State Affiliate Council past chair. He has contributed to the publication of several ASCO Policy statements on Pathways, 340B, Site-Neutrality, Safe Handling of Hazardous Drugs, and ASCO’s Patient Centered Oncology Payment model.
Nicole S. Bartosh, DO, MS, completed a fellowship in medical oncology and a residency in internal medicine at Texas A & M University Scott and White Memorial Hospital in Temple, Texas. She earned a Master's of Biomedical Science in clinical research at the University of North Texas Health Science Center, where she closely worked with breast cancer patients, evaluating a potential new treatment option for the management of hot flashes. She then went on to obtain a Doctorate of Osteopathic Medicine at the University of North Texas Health Science Center in Fort Worth. She maintains board certification in both medical oncology and internal medicine.
Cancer research continues to be a major focus for Dr. Bartosh, and she integrates clinical trials into her treatment plans to provide her patients with the most up to date treatment options. She has presented her research at both national and local meetings, has written numerous research papers, and has been published in peer-reviewed journals. She also has an interest in survivorship and community education, and speaks frequently to community groups about cancer prevention and detection.
John V. Cox, DO, MBA, FACP, FASCO, is a practicing oncologist in Dallas, Texas. In 2015, he joined UT Southwestern as the medical director of oncology services at Parkland Health and Hospital System. He completed a fellowship in medical oncology and hematology at UT Southwestern and after a stint on the faculty theren, he entered private practice in Dallas – practicing for over 25 years, most of that interval with Texas Oncology, P.A.
His interests focus on GI oncology and the delivery of care. He is the state of Texas oncology representative to the Texas Carrier Advisory Committee of Novitas. He also served as a member of CMS’ Medicare Evidence Development & Coverage Advisory Committee from 2006 to 2010.
Dr. Cox is an active volunteer with ASCO and is a liaison member of the Clinical Practice Committee, which he chaired, 2005-2006. He is a member of ASCO’s payment reform workgroup, and active in ASCO’s efforts to evaluate/codify new practice models. He has served as a member of the editorial board of the Journal of Clinical Oncology, and in January 2009, he became the editor of the Journal of Oncology Practice.
In 2018, Dr. Cox was included in D Magazine's Best Doctors list and was named a Texas Monthly "Super Doctor."
Mona Lisa Alattar, MD, is a member of the American Society of Clinical Oncology, American Society of Hematology, Iota Epsilon Alpha Society, and the National Society of Collegiate Scholars.
Eric Bernicker, MD, completed his medical training, a residency in internal medicine, and a fellowship in hematology at Baylor College of Medicine. He also completed a fellowship in medical oncology at MD Anderson Cancer Center. The goal of Dr. Bernicker's practice is to make sure that his patients get the best available treatments in a compassionate environment.
Dr. Bernicker is the primary investigator for a number of cooperative group, industry-sponsored, and investigator-initiated trials looking at different novel therapies for lung cancer, including immunotherapy. His main clinical focus is on solid tumor oncology, specifically cancers that arise in the thorax such as lung cancer, mesothelioma, head, and neck cancer, and uveal melanomas. He is also interested in targeted therapy for specific mutations that can lead to more personalized treatments for patients battling cancer.
Dr. Bernicker is an assistant clinical professor of medicine at Weill Cornell Medicine, chairman of the Houston Methodist Hospital Cancer Committee, and the liaison for the American Society of Clinical Oncology's quality program, Quality Oncology Practice Initiative. He is a member of the American Society of Clinical Oncology, the American Association for Cancer Research, and the International Association for the Study of Lung Cancer.
Luis T. Campos, MD, is a member of the American Association for Cancer Research, American Medical Association, American Society of Clinical Oncology, Texas Medical Association, Harris County Medical Society, Fort Bend Medical Society, MD Anderson Associates, and the Peruvian American Medical Society.
Sylvia Jaramillo, MD, is interested in all tumor types and has a special interest in lung, colon, and breast cancer. She values all aspects of patient care and pays particular attention to the psychosocial impact of cancer on a patient. Dr. Jaramillo's goals center on improving healthcare access to patients of disadvantaged backgrounds in order to eliminate health disparities.
Gladys Rodriguez, MD, is in private practice as a medical oncologist and hematologist with the START Center. She received her medical degree from the University of Puerto Rico School of Medicine. She completed both her internship and residency at the Veterans Administration San Juan Medical Center in Puerto Rico, and her fellowship at the University of Texas Health Science Center in San Antonio.
Dr. Rodriguez’s clinical interests include cancer treatment and new drug therapy for cancer. She served as principal investigator in multiple national and international phase III clinical trials for cancer treatment. She has special interest in access to care for cancer patients, and serves on the American Society of Clinical Oncology Health Disparity Committee and the Workforce Advisory Committee.
Laura Tenner, MD, is a faculty member in the division of hematology and medical oncology at UT Health San Antonio MD Anderson Cancer Center. She completed her medical oncology fellowship at Indiana University School of Medicine and a fellowship in clinical ethics at the Charles Warren Fairbanks Center for Medical Ethics. Dr. Tenner is board certified in both internal medicine and medical oncology with a focus in gastrointestinal cancers. She serves nationally on the American Society of Clinical Oncology Board of Ethics as well as its Cancer Prevention Committee. Her research includes using principles of ethics to help inform health services research and health policy.